TAS::75 0849::TAS; SBIR TOPIC 255, PHASE II "A STRADOBODY DIRECTED AGAINST LOW E

利妥昔单抗（Rituxan）和赫赛汀（Herceptin）是治疗淋巴瘤和乳腺癌的价值数十亿美元的产品。然而，对于某些人群，如复发性惰性NHL、HER2 IHC 2+患者和FcgR3a 158f /F多态性患者的治疗，仍然存在显著的未满足的医疗需求。该合同提案旨在：a)产生一种新的抗cd20或抗her2的新化合物，该化合物将进入临床试验，并证明比目前上市的抗体化合物具有优势；b)建立一种新的癌症治疗方法。

Background Information ¿ Rituxan¿ and Herceptin¿ are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.